|DNA-repair defects and olaparib in metastatic prostate cancer|
J Mateo, S Carreira, S Sandhu, S Miranda, H Mossop, R Perez-Lopez, ...
New England Journal of Medicine 373 (18), 1697-1708, 2015
|Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer|
ND James, SA Hussain, E Hall, P Jenkins, J Tremlett, C Rawlings, ...
New England Journal of Medicine 366 (16), 1477-1488, 2012
|Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 …|
T Powles, I Durán, MS Van Der Heijden, Y Loriot, NJ Vogelzang, ...
The Lancet 391 (10122), 748-757, 2018
|Hypoxia-regulated carbonic anhydrase IX expression is associated with poor survival in patients with invasive breast cancer|
SA Hussain, R Ganesan, G Reynolds, L Gross, A Stevens, J Pastorek, ...
British journal of cancer 96 (1), 104-109, 2007
|Virus-directed, enzyme prodrug therapy with nitroimidazole reductase: a phase I and pharmacokinetic study of its prodrug, CB1954|
G Chung-Faye, D Palmer, D Anderson, J Clark, M Downes, J Baddeley, ...
Clinical cancer research 7 (9), 2662-2668, 2001
|Pre-clinical and clinical study of QC12, a water-soluble, pro-drug of quercetin|
PJ Mulholland, DR Ferry, D Anderson, SA Hussain, AM Young, JE Cook, ...
Annals of Oncology 12 (2), 245-248, 2001
|Phase III study of cabozantinib in previously treated metastatic castration-resistant prostate cancer: COMET-1.|
M Smith, J De Bono, C Sternberg, S Le Moulec, S Oudard, U De Giorgi, ...
|The systemic treatment of advanced and metastatic bladder cancer|
SA Hussain, ND James
The Lancet Oncology 4 (8), 489-497, 2003
|Chemotherapy for breast cancer|
MSU Hassan, J Ansari, D Spooner, SA Hussain
Oncology reports 24 (5), 1121-1131, 2010
|Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle‐invasive bladder cancer|
MD Galsky, SK Pal, S Chowdhury, LC Harshman, SJ Crabb, YN Wong, ...
Cancer 121 (15), 2586-2593, 2015
|Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised …|
DP Petrylak, R De Wit, KN Chi, A Drakaki, CN Sternberg, H Nishiyama, ...
The Lancet 390 (10109), 2266-2277, 2017
|The detection of hepatocellular carcinoma using a prospectively developed and validated model based on serological biomarkers|
PJ Johnson, SJ Pirrie, TF Cox, S Berhane, M Teng, D Palmer, J Morse, ...
Cancer Epidemiology and Prevention Biomarkers 23 (1), 144-153, 2014
|Phase III, double-blind, randomized trial that compared maintenance lapatinib versus placebo after first-line chemotherapy in patients with human epidermal growth factor …|
T Powles, RA Huddart, T Elliott, SJ Sarker, C Ackerman, R Jones, ...
Journal of Clinical Oncology 35 (1), 48-55, 2017
|A phase I/II study of gemcitabine and fractionated cisplatin in an outpatient setting using a 21-day schedule in patients with advanced and metastatic bladder cancer|
SA Hussain, DD Stocken, P Riley, DH Palmer, DR Peake, JI Geh, ...
British journal of cancer 91 (5), 844-849, 2004
|Systemic therapies for hepatocellular carcinoma|
DH Palmer, SA Hussain, PJ Johnson
Expert opinion on investigational drugs 13 (12), 1555-1568, 2004
|The Nrf2 transcription factor contributes to resistance to cisplatin in bladder cancer|
A Hayden, J Douglas, M Sommerlad, L Andrews, K Gould, S Hussain, ...
Urologic Oncology: Seminars and Original Investigations 32 (6), 806-814, 2014
|Randomized noninferiority trial of reduced high-dose volume versus standard volume radiation therapy for muscle-invasive bladder cancer: results of the BC2001 trial (CRUK/01/004)|
RA Huddart, E Hall, SA Hussain, P Jenkins, C Rawlings, J Tremlett, ...
International Journal of Radiation Oncology* Biology* Physics 87 (2), 261-269, 2013
|BCL2 expression predicts survival in patients receiving synchronous chemoradiotherapy in advanced transitional cell carcinoma of the bladder|
SA Hussain, R Ganesan, L Hiller, PW Cooke, P Murray, LS Young, ...
Oncology reports 10 (3), 571-576, 2003
|Long-term results of a phase II study of synchronous chemoradiotherapy in advanced muscle invasive bladder cancer|
SA Hussain, DD Stocken, DR Peake, JG Glaholm, A Zarkar, DMA Wallace, ...
British journal of cancer 90 (11), 2106-2111, 2004
|A randomised phase 2 study of AZD2014 versus everolimus in patients with VEGF-refractory metastatic clear cell renal cancer|
T Powles, M Wheater, O Din, T Geldart, E Boleti, A Stockdale, S Sundar, ...
European urology 69 (3), 450-456, 2016